Preclinical evaluation of non-imidazole histamine H3 receptor antagonists in comparison to atypical antipsychotics for the treatment of cognitive deficits associated with schizophrenia

International Journal of Neuropsychopharmacology

Volumn 16, Issue 4, 2013, Pages 889-904

  Brown, Jordan W ^a   Whitehead, Caroline A ^a   Basso, Ana M ^a   Rueter, Lynne E ^a   Zhang, Min ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Antipsychotic; cognition; H3 receptor antagonist; schizophrenia

Indexed keywords

5 (4 CYANOPHENYL) 2 [2 (2 METHYL 1 IMIDAZOLIDINYL)ETHYL]BENZOFURAN; A 431404; DIZOCILPINE; HISTAMINE H3 RECEPTOR ANTAGONIST; KETAMINE; METHYLAZOXYMETHANOL ACETATE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OLANZAPINE; RISPERIDONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; COGNITIVE DEFICIT ASSOCIATED WITH SCHIZOPHRENIA; CROSS MAZE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG SCREENING; EXPERIMENTAL TEST; LONG TERM MEMORY; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; WORKING MEMORY;

ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; COGNITION DISORDERS; DRUG EVALUATION, PRECLINICAL; HISTAMINE H3 ANTAGONISTS; IMIDAZOLES; MALE; RATS, LONG-EVANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 84875736286     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145712000739     Document Type: Article

References (79)

1. Adler CM, Goldberg TE, Malhotra AK, Pickar D, et al. (1998). Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers. Biological Psychiatry 43, 811-816.
2. Antonova E, Sharma T, Morris R, Kumari V (2004). The relationship between brain structure and neurocognition in schizophrenia: a selective review. Schizophrenia Research 70, 117-145.
3. Arrang JM, Garbarg M, Schwartz JC (1983). Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 302, 832-837.
4. Barak S, Weiner I (2011). The M1/M4 preferring agonist xanomeline reverses amphetamine-, MK801-and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia. International Journal of Neuropsychopharmacology 14, 1233-1246.
5. Barch DM, Carter CS, Arnsten A, Buchanan RW, et al. (2009). Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting. Schizophrenia Bulletin 35, 109-114.
6. Bardgett ME, Points M, Kleier J, Blankenship M, et al. (2010). The H3 antagonist, ciproxifan, alleviates the memory impairment but enhances the motor effects of MK-801 (dizocilpine) in rats. Neuropharmacology 59, 492-502.
7. Bardgett ME, Points M, Roflow J, Blankenship M, et al. (2009). Effects of the H(3) antagonist, thioperamide, on behavioral alterations induced by systemic MK-801 administration in rats. Psychopharmacology 205, 589-597.
8. Basso AM, Curzon P, Zhang M, Gallagher KB, et al. (2010). Neonatal treatment with methylazoxymethanol acetate (MAM) as a neurodevelopmental model of schizophrenia: behavioral, pharmacological and morphological characterization. Schizophrenia Research 117, 272-273.
9. Bernaerts P, Lamberty Y, Tirelli E (2004). Histamine H3 antagonist thioperamide dose-dependently enhances memory consolidation and reverses amnesia induced by dizocilpine or scopolamine in a one-trial inhibitory avoidance task in mice. Behavioral Brain Research 154, 211-219.
10. Blandina P, Giorgetti M, Bartolini L, Cecchi M, et al. (1996). Inhibition of cortical acetylcholine release and cognitive performance by histamine H3 receptor activation in rats. British Journal of Pharmacology 199, 1656-1664.
11. Brioni JD, Esbenshade TA, Garrison TR, Bitner SR, et al. (2010). Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease. Journal of Pharmacology and Experimental Therapeutics 336, 38-46.
12. Carter CS, Barch DM, Buchanan RW, Bullmore E, et al. (2008). Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the cognitive neuroscience treatment research to improve cognition in schizophrenia initiative. Biological Psychiatry 64, 4-10.
13. Charlier Y, Tirelli E (2011). Differential effects of histamine H(3) receptor inverse agonist thioperamide, given alone or in combination with the N-methyl-d-aspartate receptor antagonist dizocilpine, on reconsolidation and consolidation of a contextual fear memory in mice. Neuroscience 193, 132-142.
14. Chen Z, Zhao Q, Sugimoto Y, Fujii Y, et al. (1999). Effects of histamine on MK-801-induced memory deficits in radial maze performance in rats. Brain Research 839, 186-189.
15. Chin CL, Curzon P, Schwartz AJ, O'Connor EM, et al. (2010). Structural abnormalities revealed by magnetic resonance imaging in rats prenatally exposed to methylazoxymethanol acetate parallel cerebral pathology in schizophrenia. Synapse 65, 393-403.
16. Conley RR, Meltzer HY (2000). Adverse events related to olanzapine. Journal of Clinical Psychiatry 61 (Suppl. 8), 26-29.
17. Corbett R, Camacho F, Woods AT, Kerman LL, et al. (1995). Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology 120, 67-74.
18. Coyle JT (2006). Glutamate and schizophrenia: beyond the dopamine hypothesis. Cellular and Molecular Neurobiology 26, 365-384.
19. Drutel G, Peitsaro N, Karlstedt K, Wieland K, et al. (2001). Identification of rat H3 receptor isoforms with different brain expression and signaling properties. Molecular Pharmacology 59, 1-8.
20. Enomoto T, Ishibashi T, Tokuda K, Ishiyama T, et al. (2008). Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behavioral Brain Research 186, 197-207.
21. Esbenshade TA, Browman KE, Bitner RS, Strakhova M, et al. (2008). The histamine H3 receptor: an attractive target for the treatment of cognitive disorders. British Journal of Pharmacology 154, 1166-1181.
22. Esbenshade TA, Fox GB, Cowart MD (2006). Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders. Molecular Interventions 6, 77-88.
23. Esbenshade TA, Fox GB, Krueger KM, Miller TR, et al. (2005). Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl} -benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties. Journal of Pharmacology and Experimental Therapeutics 313, 165-175.
24. Farber NB (2003). The NMDA receptor hypofunction model of psychosis. Annals of the New York Academy of Sciences 1003, 119-130.
25. Fatemi SH, Folsom TD (2009). The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophrenia Bulletin 35, 528-548.
26. Flagstad P, Glenthoj BY, Didriksen M (2005). Cognitive deficits caused by late gestational disruption of neurogenesis in rats: a preclinical model of schizophrenia. Neuropsychopharmacology 30, 250-260.
27. Fox GB, Esbenshade TA, Pan JB, Radek RJ, et al. (2005). Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5- yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. Journal of Pharmacology and Experimental Therapeutics 313, 176-190.
28. Fox GB, Pan JB, Lewis AM, Browman KE, et al. (2004). Cognition enhancing effects of novel H(3) receptor (H(3)R) antagonists in several animals models. Inflammation Research 53 (Suppl. 1), S49-S50.
29. Ghoneim MM, Hinrichs JV, Mewaldt SP, Petersen RC (1985). Ketamine: behavioral effects of subanesthetic doses. Journal of Clinical Psychopharmacology 5, 70-77.
30. Gleason SD, Shannon HE (1997). Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology 129, 79-84.
31. Gold PE (1986). The use of avoidance training in studies of modulation of memory storage. Behavioral and Neural Biology 46, 87-98.
32. Graef S, Schonknecht P, Sabri O, Hegerl U (2011). Cholinergic receptor subtypes and their role in cognition, emotion, and vigilance control: an overview of preclinical and clinical findings. Psychopharmacology 215, 205-229.
33. Green MF, Kern RS, Braff DL, Mintz J (2000). Neurocognitive deficits and functional outcomes in schizophrenia: are we measuring the 'right stuff'? Schizophrenia Bulletin 26, 119-136.
34. Grunze HC, Rainnie DG, Hasselmo ME, Barkai E, et al. (1996). NMDA-dependent modulation of CA1 local circuit inhibition. Journal of Neuroscience 16, 2034-2043.
35. Buccafusco JJ (Ed.), Basel, Switzerland: Birkhauser Verlag. Hancock AA, Fox GB (2004). Cognitive enhancing effects of drugs that target histamine receptors. In: Buccafusco JJ (Ed.), Cognitive Enhancing Drugs Milestones in Drug Therapy (pp. 97-114). Basel, Switzerland: Birkhauser Verlag.
36. Harrison PJ, Weinberger DR (2005). Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Molecular Psychiatry 10, 40-68.
37. Hazane F, Krebs MO, Jay TM, Le Pen G (2009). Behavioral perturbations after prenatal neurogenesis disturbance in female rat. Neurotoxicity Research 15, 311-320.
38. Heinrichs RW, Zakzanis KK (1998). Neurocogntive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 12, 426-445.
39. Huang YW, Hu WW, Chen Z, Zhang LS, et al. (2004). Effect of the histamine H3-antagonist clobenpropit on spatial memory deficits induced by MK-801 as evaluated by radial maze in Sprague-Dawley rats. Behavioral Brain Research 151, 287-293.
40. Ishiyama T, Tokuda K, Ishibashi T, Ito A, et al. (2007). Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. European Journal of Pharmacology 572, 160-170.
41. Izquierdo LA, Barros DM, Vianna MR, Coitinho A, et al. (2002). Molecular pharmacological dissection short-and long-term memory. Cellular Molecular Neurobiology 22, 269-287.
42. Jackson ME, Homayoun H, Moghaddam B (2004). NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proceedings of the National Academy of Sciences USA 101, 8467-8472.
43. Jaaro-Peled H (2009). Gene models of schizophrenia: DISC1 mouse models. Progress in Brain Research 179, 75-86.
44. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry 148, 1301-1308.
45. Keefe RS, Bilder RM, Davis SM, Harvey PD, et al. (2007). Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Archives of General Psychiatry 64, 633-647.
46. Krystal JH, D'Souza DC, Mathalon D, Perry E, et al. (2003). NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology 169, 215-233.
47. Krystal JH, Karper LP, Seibyl JP, Freeman GK, et al. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archives of General Psychiatry 51, 199-214.
48. Lalonde R (2002). The neurobiological basis of spontaneous alternation. Neuroscience and Biobehavioral Reviews 26, 91-104.
49. Large CH (2007). Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs? Journal of Psychopharmacology 21, 283-301.
50. Le Pen G, Gourevitch R, Hazane F, Hoareau C, et al. (2006). Peri-pubertal maturation after developmental disturbance: a model for psychosis onset in the rat. Neuroscience 143, 395-405.
51. Lodge DJ, Behrens MM, Grace AA (2009). A loss of parvalbumin-containing interneurons is associated with diminshed oscillatory activity in an animal model of schizophrenia. Journal of Neuroscience 29, 2344-2354.
52. Lodge DJ, Grace AA (2007). Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia. Journal of Neuroscience 27, 11424-11430.
53. Lodge DJ, Grace AA (2009). Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia. Behavioral Brain Research 204, 306-312.
54. Lublin H, Eberhard J, Levander S (2005). Current therapy issues and unmet clinical need in the treatment of schizophrenia: a review of the new generation antipsychotics. International Clinical Psychopharmacology 20, 183-198.
55. Luby ED, Cohen RC, Rosenbaum B, Gottlieb JS, et al. (1959). Study of a new schizophrenomimetic drug: Sernyl. A.M.A. Archives of Neurology and Psychiatry 81, 363-369.
56. McGaugh JL (1966). Time-dependent processes in memory storage. Science 153, 1351-1358.
57. McGrath BM, Tempier RP (2005). Patients' opinions of olanzapine and risperidone following long-term treatment: results from a cross-sectional survey. Pharmacopsychiatry 38, 147-157.
58. McKibben CE, Jenkins TA, Adams HN, Harte MK, et al. (2010). Effect of pretreatment with risperidone on phencyclidine-induced disruptions in object recognition memory and prefrontal cortex parvalbumin immunoreactivity in the rat. Behavioral Brain Research 208, 132-136.
59. Malhotra AK, Pinals DA, Adler CM, Elman I, et al. (1997). Ketamine-induced exacerbation of psychotic symptoms and cognitive impairments in neuroleptic-free schizophrenics. Neuropsychopharmacology 17, 141-150.
60. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, et al. (1996). NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14, 310-307.
61. Marenco S, Weinberger DR (2000). The neurodevelopmental hypothesis of schizophrenia: following a trail of evidence from cradle to grave. Development and Psychopathology 12, 501-527.
62. Miller DD (2004). Atypical antipsychotics: sleep, sedation, and efficacy. Primary Care Companion to the Journal of Clinical Psychiatry 6 (Suppl. 2), 3-7.
63. Moghaddam B, Adams B, Verma A, Daly D (1997). Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. Journal of Neuroscience 17, 2921-2927.
64. Moore H, Jentsch JD, Ghajarnia M, Geyer MA, et al. (2006). A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. Biological Psychiatry 60, 253-264.
65. Myhrer T (2003). Neurotransmitter systems involved in learning and memory in the rat: a meta-analysis based on studies of four behavioral tasks. Brain Research, Brain Research Reviews 41, 267-287.
66. NishigaM, Kamei C (2003). Ameliorative effects of histamine on 7-chlorokynurenic acid-induced spatial memory deficits in rats. Psychopharmacology 166, 360-365.
67. Olney JW, Farber NB (1995). Glutamate receptor dysfunction and schizophrenia. Archives of General Psychiatry 52, 998-1007.
68. Passani MB, Bacciottini L, Mannaioni PF, Blandina P (2000). Central histaminergic system and cognition. Neuroscience and Biobehavioral Reviews 24, 107-113.
69. Penschuck S, Flagstad P, Didriksen M, Leist M, et al. (2006). Decrease in parvalbumin-expressing neurons in the hippocampus and increased phencyclidine-induced locomotor activity in the rat methylazoxymethanol (MAM) model of schizophrenia. European Journal of Neuroscience 23, 279-284.
70. Ragozzino ME, Pal SN, Unick K, Stefani MR, Gold PE (1998). Modulation of hippocampal acetylcholine release and spontaneous alternation scores by intrahippocampal glucose injections. Journal of Neuroscience 18, 1595-1601.
71. Ragozzino ME, Unick KE, Gold PE (1996). Hippocampal acetylcholine release during memory testing in rats: augmentation by glucose. Proceedings of the National Academy of Sciences USA 93, 4693-4698.
72. Rehn AE, Rees SM (2005). Investigating the neurodevelopmental hypothesis of schizophrenia. Clinical and Experimental Pharmacology and Physiology 32, 687-696.
73. Roberts BM, Seymour PA, Schmidt CJ, Williams GV, et al. (2010). Amelioration of ketamine-induced working memory deficits by dopamine D1 receptor agonists. Psychopharmacology 210, 407-418.
74. Rossler W, Sailze HJ, van OS J, Riecher-Rossler A (2005). Size of burden of schizophrenia and psychotic disorders. European Neuropsychopharmacology 15, 399-409.
75. Rowland LM, Astur RS, Jung RE, Bustillo JR, et al. (2005). Selective cognitive impairments associated with NMDA receptor blockade in humans. Neuropsychopharmacology 30, 633-639.
76. Tseng Ky, Chambers RA, Lipska BK (2009). The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia. Behavioral Brain Research 204, 295-305.
77. Velligan DI, Bow-Thomas CC, Mahurin RK, Miller AL, et al. (2000). Do specific neurocognitive deficits predict specific domains of community function in schizophrenia? Journal of Nervous Disease and Mental Health 188, 518-524.
78. Xu LS, Yang LX, Hu WW, Yu X, et al. (2005). Histamine ameliorates spatial memory deficits induced by MK-801 infusion into ventral hippocampus as evaluated by radial maze task in rats. Acta Pharmacologica Sinica 26, 1448-1453.
79. Zhang M, Ballard ME, Pan L, Roberts S, et al. (2005). Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs. Brain Research 1045, 142-149.